First peoples Hospital of Xiaoshan District of Hangzhou City

Hangzhou, China

First peoples Hospital of Xiaoshan District of Hangzhou City

Hangzhou, China
SEARCH FILTERS
Time filter
Source Type

Yao J.,First Peoples Hospital Of Xiaoshan District Of Hangzhou City | Zhan P.-C.,First Peoples Hospital Of Xiaoshan District Of Hangzhou City | Cheng W.,First Peoples Hospital Of Xiaoshan District Of Hangzhou City
World Chinese Journal of Digestology | Year: 2017

AIM To investigate the clinical prognosis of patients with gastric cancer who develop urinary tract obstruction after total gastrectomy. METHODS Patients with urinary tract obstruction secondary to gastrectomy after total gastrectomy plus Roux-en-Y anastomosis at our department between January 2005 and June 2015 were retrospectively reviewed. All the patients came to our hospital regularly for review. We recorded their gender and age, urinary tract obstruction, chemotherapy, histological type of gastric cancer, gastric cancer stage, metastasis, survival rate, urinary tract obstruction time, survival time, tumor-free survival time, and the remaining survival time. RESULTS Twenty-eight patients with urinary tract obstruction secondary to total gastrectomy were included. In 12 cases, urinary tract obstruction was found for the first time with no evidence of tumor recurrence; their median time to development of urinary tract obstruction after gastrectomy was 18 mo (range, 6-48 mo), median tumor-free survival t i me was 6 mo (3-22 mo), and median remaining survival time was 8 mo (4-30 mo). In 16 cases, urinary tract obstruction was found for the first time with evidence of tumor recurrence; their median time to development of urinary tract obstruction after gastrectomy was 16 mo (3-42 mo) and median remaining survival time was 6 mo (3-24 mo). There was no significant difference in the median time to development of urinary tract obstruction after gastrectomy or the median remaining survival time (P > 0.05). The median survival time of 28 patients with urinary tract obstruction after total gastrectomy was 30 mo (6-72 mo). CONCLUSION The prognosis of patients with urinary tract obstruction after total gastrectomy is poor. In patients with urinary tract obstruction after total gastrectomy, tumor recurrence and metastasis should be considered. © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.


Gu S.-J.,First peoples Hospital of Xiaoshan District of Hangzhou City | Xuan H.-F.,First peoples Hospital of Xiaoshan District of Hangzhou City | Lu M.,First peoples Hospital of Xiaoshan District of Hangzhou City | Chen X.-Z.,First peoples Hospital of Xiaoshan District of Hangzhou City | And 6 more authors.
Clinica Chimica Acta | Year: 2013

Background: Visfatin, a proinflammatory mediator, has been associated with poor clinical outcomes after acute brain injury. The present study is designed to investigate the potential association between plasma visfatin levels and the risk of hematoma growth (HG) and early neurologic deterioration (END) after intracerebral hemorrhage. Methods: There were 85 patients as cases who presented with first-time hemorrhagic stroke that were assessed within 6. h after the incident. The control group consisted of 85 healthy volunteers. HG was defined as hematoma enlargement >. 33% at 24. h. END was defined as an increase of. ≥. 4 points in National Institute of Health Stroke Scale score at 24. h from symptoms onset. Plasma visfatin levels were determined using enzyme immunoassay. Results: Plasma visfatin levels were significantly higher in patients compared to controls. Plasma visfatin level emerged as an independent predictor of HG [odds ratio (OR), 1.154; 95% confidence interval (CI), 1.046-3.108; P=. 0.009] and END (OR, 1.195; 95% CI, 1.073-3.516; P=. 0.005). For predicting HG, area under curve (AUC) of plasma visfatin level (0.814; 95% CI: 0.715-0.890) was similar to that of hematoma volume (0.839; 95% CI, 0.743-0.909) (. P=. 0.703). For predicting END, AUC of plasma visfatin level (0.828; 95% CI: 0.730-0.901) was similar to that of hematoma volume (0.863; 95% CI, 0.771-0.928) (. P=. 0.605). Visfatin did not improve AUC of hematoma volume for predicting HG and END (both P>. 0.05). Conclusion: Plasma visfatin level represents a novel biomarker for predicting HG and END. © 2013 Elsevier B.V.

Loading First peoples Hospital of Xiaoshan District of Hangzhou City collaborators
Loading First peoples Hospital of Xiaoshan District of Hangzhou City collaborators